These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 25727557)

  • 1. Landscape of neoadjuvant therapy for breast cancer.
    Haddad TC; Goetz MP
    Ann Surg Oncol; 2015 May; 22(5):1408-15. PubMed ID: 25727557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multidisciplinary approach to neoadjuvant therapy for primary operable breast cancer. Challenges and opportunities.
    Connolly R; Stearns V
    Oncology (Williston Park); 2010 Feb; 24(2):135-43. PubMed ID: 20361464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement.
    Colomer R; Saura C; Sánchez-Rovira P; Pascual T; Rubio IT; Burgués O; Marcos L; Rodríguez CA; Martín M; Lluch A
    Oncologist; 2019 May; 24(5):603-611. PubMed ID: 30710068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug development: neoadjuvant opportunities in breast cancer.
    Rastogi P; Geyer CE; Mamounas EP; DeMichele A
    Am Soc Clin Oncol Educ Book; 2013; ():73-9. PubMed ID: 23714461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints.
    Yeo B; Dowsett M
    Breast; 2015 Nov; 24 Suppl 2():S78-83. PubMed ID: 26255746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy in breast cancer: review of literature.
    Doval DC; Dutta K; Batra U; Talwar V
    J Indian Med Assoc; 2013 Sep; 111(9):629-31. PubMed ID: 24968534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Therapy for HER2-positive Breast Cancer.
    Wuerstlein R; Harbeck N
    Rev Recent Clin Trials; 2017; 12(2):81-92. PubMed ID: 28164759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
    Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
    Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
    Franceschini G; Di Leone A; Natale M; Sanchez MA; Masett R
    Ann Ital Chir; 2018; 89():290. PubMed ID: 30352955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of breast cancer therapy: biomarker-driven and response-guided approaches in a neoadjuvant setting.
    Toi M; Masuda N; Ishiguro H; Saji S; Ohno S; Chow LW
    Int J Biol Markers; 2015; 30(2):e252-3. PubMed ID: 25684439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers of residual disease after neoadjuvant therapy for breast cancer.
    Penault-Llorca F; Radosevic-Robin N
    Nat Rev Clin Oncol; 2016 Aug; 13(8):487-503. PubMed ID: 26856744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translating neoadjuvant therapy into survival benefits: one size does not fit all.
    De Mattos-Arruda L; Shen R; Reis-Filho JS; Cortés J
    Nat Rev Clin Oncol; 2016 Sep; 13(9):566-79. PubMed ID: 27000962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy.
    King TA; Morrow M
    Nat Rev Clin Oncol; 2015 Jun; 12(6):335-43. PubMed ID: 25850554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Processing and Reporting of Breast Specimens in the Neoadjuvant Setting.
    Bossuyt V
    Surg Pathol Clin; 2018 Mar; 11(1):213-230. PubMed ID: 29413658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neoadjuvant systemic therapy in breast cancer].
    Kahán Z; Nikolényi A; Uhercsák G; Thurzó L
    Orv Hetil; 2009 Jan; 150(2):65-71. PubMed ID: 19103557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
    Freedman OC; Verma S; Clemons MJ
    Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy: A Review of the Evidence.
    Chapman CH; Jagsi R
    Oncology (Williston Park); 2015 Sep; 29(9):657-66. PubMed ID: 26384802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Endocrine Therapy in Breast Cancer Upregulates the Cytotoxic Drug Pump ABCG2/BCRP, and May Lead to Resistance to Subsequent Chemotherapy.
    Baxter DE; Kim B; Hanby AM; Verghese ET; Sims AH; Hughes TA
    Clin Breast Cancer; 2018 Dec; 18(6):481-488. PubMed ID: 30055962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.